Apr 28, 2020
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Mar 24, 2020
When Mothers Receive Fentanyl Epidurals During Labor, the Fentanyl Gets Passed on to Their Babies
Mar 24, 2020
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Mar 18, 2020
Nutriband Inc. Receives Patent Protection from Australia, Russia and Mexico
Dec 11, 2019
FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug
Oct 18, 2019
America's endless battle against lethal drug fentanyl
Oct 11, 2019
Dana Point Rehab Campus CEO Michael Castanon Discusses the Fentanyl Crisis on CBS-LA
Oct 01, 2019
Test Helps Identify Newborns Exposed to Fentanyl Abuse
Jul 17, 2019
Millennium Health Fentanyl Test Offering Expanded to Address Latest DEA Emerging Threat Report
Apr 24, 2019
Health, Science Take Center Stage at Rx Drug Abuse & Heroin Summit
Mar 28, 2019
Baymark Health Services Opens Two AppleGate Recovery Clinics in Ohio
Feb 25, 2019
Recovery Advocates to the FDA: WAKE UP
Feb 01, 2019
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
Jan 10, 2019
SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)
Jan 08, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS
Jan 03, 2019
Stepping Sober Praises Agreement Between Trump and Chinese Government
Nov 01, 2018
Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
Nov 01, 2018
Trading in Alkermes Ordinary Shares Halted Today
Oct 29, 2018
Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry
Oct 23, 2018
908 Devices' MX908 out-designs designer drugs